Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|June 14, 2019
OGT Expands Product Portfolio with Complete Library Preparation Solution
Author(s)Pharmaceutical Technology Editors
OGT has announced the expansion of its SureSeq portfolio with a complete library preparation solution for hybridization-based target capture in NGS.
Advertisement
Oxford Gene Technology (OGT) has announced the expansion of its SureSeq portfolio with a complete library preparation solution for hybridization-based target capture in next-generation sequencing (NGS).
Through the expansion, which includes an updated and refined library preparation workflow, as well as a new, ready-to-use hybridization and wash buffer, OGT has made its MGS coverage and expertise more accessible. The SureSeq NGS portfolio features targeted panels, library preparation kits, and a software package.
“With this expansion of our SureSeq portfolio, we have further broken down the barriers for hybridization in NGS, making it quicker, easier, and more flexible, while also delivering enormous benefits to researchers in terms of data quality,” said John Anson, CEO of OGT in a June 13, 2019 press release. “OGT has a reputation for quality and expertise and together with Sysmex we see NGS as a key future technology. As part of a large, global IVD company, we are exploring many exciting possibilities, and it is our aim that future development plans in this area will be transformative for our customers.”
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
Complying with International Pharmacopoeias
5